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Abstract 
Background: A series of structurally related 2-aryl-4-(amino/methoxy)quinoline 
derivatives were evaluated for potential antimycobacterial activity against Myco-
bacterium tuberculosis strain H37Rv. 
Methods: The chemical compounds were tested against a drug sensitive and 
drug-resistant strains of M. tuberculosis using rapid radiometric techniques. The 
selected derivatives were tested for their intracellular activity against TB- infected 
macrophages. Two 4-amino-2,3-diarylquinoline derivatives were investigated for 
their immune modulatory effect with regard to to Th1 and Th2-subset cytokines
Results: A complete inhibition of a drug sensitive strain of M. tuberculosis was 
observed at 20.0 µg/mL for 4-amino-2-(4-chlorophenyl)quinoline 3b, 4-amino-3-
iodo-2-(4-methoxyphenyl)quinoline 5d, 4-amino-2,3-diphenylquinoline 6a, 4-ami-
no-2-(4-fluorophenyl)-3-phenylquinoline 6b and 4-amino-2-(4-methoxyphenyl)-3-
phenylquinoline 6d. These derivatives were further evaluated for activity against a 
multidrug resistant strain of M. tuberculosis. The minimum inhibitory concentration 
(MIC) against a two drug-resistant strain was found to be ≥5.0≤20.0 µg/mL. Sys-
tems 6a and 6b were, in turn, subjected to cytotoxicity assay using U937 human 
macrophages and their subsequent intracellular antimycobacterial activity was de-
termined. Intracellular M. tuberculosis growth was inhibited with 64 and 61% by 
compounds 6a and 6b, at concentrations of 18.00 and 14.00 µg/mL, respectively. 
Moreover, these two 4-amino-2,3-diarylquinoline derivatives were also investigated 
for their immune modulatory effect according to Th1 and Th2-subset cytokines. 
System 6b indicated activity that stimulated multi-effector macrophages with a 
mixed Th1/Th2 cytokine profile.
Conclusions: The presence of a primary amino group at C-4 and phenyl ring at 
C-3 and the accompanying increased basicity of the quinoline ring as well as elec-
tronic effect and lipophilicity of the substituent on the para position of the 2-phenyl 
ring seem to be critical for the antimycobacterial activity of the 2,3-diarylquinoline 
derivatives. Overall, the production of cytokines from this specific experiment gives 
an idea of the amount of individual cytokines produced daily instead of a cumula-
tive response to the test samples during infection. Compound 6a holds potential 
to modulate the functionality of M. tuberculosis infected macrophages.
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Introduction
Tuberculosis (TB) is a contagious disease caused by respiratory 
infection from the Gram positive bacteria, Mycobacterium 
tuberculosis, and this disease remains one of the major world 
health problem with an estimated annual death toll of about 
2 million [1]. The situation is further complicated by the as-
sociation of TB with HIV infections [2] and the emergence 
of multidrug resistant (MDR) strains of M. tuberculosis [3]. 
The multidrug resistant strains of M. tuberculosis have be-
come insensitive to one or more of the first-line drugs cur-
rently in the market, viz., streptomycin (STR), isoniazid (INH), 
ethambutol (ETH), pyrazinamide (PA) and rifampicin (RIF) [3]. 
Moreover, it is well known that M. tuberculosis survive in 
macrophages by various mechanisms and that anti-TB drugs 
that are effective in the acidic vacuoles of macrophages are 
needed for the treatment of TB [4-6]. Several fluoroquino-
line antibacterial drugs have previously been examined as po-
tential chemotherapeutics for M. tuberculosis infection [7]. 
The naturally occurring 4-methoxy-2-phenylquinoline and its 
2-(methylenedioxyphenyl) analogue have recently been found 
to show inhibitory activity against M. tuberculosis H37Rv [8]. 
The analogous 4-aminoquinolines are known to exhibit an-
timalarial, anti-inflammatory, antibacterial, and antihyperten-
sive activities [9] and some derivatives have also been found 
to serve as immunostimulants [10] and non-nucleoside HIV-1 
inhibitors [11]. 
In the absence of an obvious immunosuppressive disorder 
such as HIV infection, the tubercle bacillus is non-pathogenic 
in 90% of those individuals infected [12, 13]. There are two 
types of T cell mediated immune responses against tubercu-
losis infection [14]. T cells are divided into mainly two subsets 
depending on the different cytokines produced, type 1 helper 
T cells (Th1; characterized by the production of IL-2, IL-12, 
IFN-γ and TNF-α) and type 2 helper T cells (Th2; character-
ized by the production of IL-4, IL-5 and IL-10). A predominant 
Th2-type cell response causes tissue damage and may, under 
some circumstances, have a minor protective role by isolat-
ing bacteria in necrotic foci. However, the immune response 
associated with a Th2 cell profile does not actively destroy 
tubercle bacilli and thus does not lead to sterilisation of the 
tissues. The second type of response is associated with Th1-
type cells that induce a state of protective immunity (14). 
It has been proposed that a balanced stimulation of both 
responses is necessary for protective responses accompanied 
by minimal immunopathology [15].
Understanding of how the immune response and functioning 
is controlled by delicate balances between these two distinct 
subsets, based on cell cytokine profile, has increased dramati-
cally in recent years [16]. Immune functions are mediated by 
the secretion of cytokines in a supposedly polarized fashion, 
classified as either Th1- or Th2-type cytokines [17]. Th1-type 
cytokines include mainly IFN-γ, IL-2 and IL-12 secretions [18, 
19]. Th1 cells also secrete TNF, thereby enhancing B-cell re-
sponses that elicit IgG2a, the antibody subclass most effi-
cient in binding the serum complement proteins that enhance 
antigen-antibody reactions [18]. Th2 cells express IL-4, IL-5, 
IL-10 and IL-13 [19, 20] that activate the production of high 
levels of IgG1, IgA, and IgE by B cells [18]. This cytokine het-
erogeneity is not restricted to CD4+ T cells, as other cell types 
also contribute to the secretion of regulatory cytokines. Thus, 
the terms Th1-type and Th2-type cytokines or cells are used 
to characterize the cytokine profile of different cell types. Im-
munological findings indicate that a therapeutic measure able 
to switch from a Th2 to a Th1 response would be of great 
benefit in treating TB [17, 18, 21]. In this context, compounds 
that can induce the Th1 response and subsequently suppress 
the Th2 response by increasing or decreasing the related cy-
tokines can be valuable for anti-TB treatments. 
The alarming increase in bacterial infections that have become 
resistant to most commonly used antibiotics prompted us to 
probe the known 4-methoxy-2-arylquinoline and 4-amino-
2-arylquinoline derivatives [22-24] for potential antibacterial 
activity on M. tuberculosis. The cytotoxicity of the systems 
found to exhibit direct inhibitory antimycobacterial activity 
was determined using the U937 monocytic cell line, which 
maintains potential to differentiate macrophages upon stimu-
lation. Moreover, their intracellular antimycobacterial activity 
was also determined. In light of previous results for 4-amino-
quinolines serving as immunostimulants [10], the possibility 
that the present analogues can increase or decrease specific 
cytokine levels intracellularly in naive and M. tuberculosis in-
fected U937 macrophages was also investigated. 
Materials and Methods
General
A drug-susceptible strain of M. tuberculosis (sensitive to the 
first-line antituberculous drugs; INH, RIF, ETH and STR), H37Rv 
(ATCC 27294) was obtained from the American Type Cul-
ture Collection (Rockville, MD, USA). The two drug-resistant 
strain of M. tuberculosis (AW 4/2), resistant to both INH 
and ETH, was obtained from a clinical specimen (Medical 
Research Council, Pretoria [MRC], South Africa). All proce-
dures involving manipulation of mycobacteria were carried 
out in a biological safety cabinet (Level 3, MRC). 4-Amino-
2-arylquinolines 3a–c, 4-amino-2-aryl-3-bromoquinolines 
4a–d, 4-amino-2-aryl-3-iodoquinolines 5a–d, 4-amino-2,3-
diarylquinolines 6a–d, 2-aryl-3-iodo-4-methoxyquinolines 
7a–d and 2,3-diaryl-4-methoxyquinolines 8a–d used in this 
investigation (Figure. 1.) were synthesized as described in our 
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previous communications [22-24]. The test compounds were 
prepared in DMSO at concentrations of 5–20 µg/mL.
 
Preparation of micro-organisms
The micro-organisms, H37Rv drug-sensitive strain and the 
clinical drug-resistant strain (AW 4/2) of Mycobacterium 
tuberculosis, were plated onto slants of Löwenstein-Jensen 
(LJ) medium and allowed to grow for 3-4 weeks at 37 °C. 
The H37Rv reference strain of M. tuberculosis was used in 
the screening procedure and the AW4/2 strain was used in 
the subsequent activity assays at the MRC, Pretoria, South 
Africa. Both the strains were maintained and prepared in the 
same way. A representative amount of growth was taken 
from the LJ cultures by using a sterile applicator stick. This 
sample was transferred to a sterile 16×125 mm screw capped 
round tube containing six to eight glass beads (1-2 mm) 
and 3.0-4.0 mL of the diluting fluid (0.1% Tween 80/saline 
solution). The culture mixture was homogenised by mixing 
the tube on a Vortex mixer for 5-10 minutes. A homogenous 
suspension was obtained by placing the tube on the Vortex 
mixer for five minutes and then left for 15 minutes to allow 
the particles to settle. After the large particles had settled, 
the supernatant was transferred into a separate sterile test 
tube and more diluting fluid was added and adjusted to 
McFarland no. 1 turbidity standard (1×104 to 1×105 colony-
forming units per millilitre [CFU/mL]). A hundred microlitres 
of the adjusted growth suspension was streaked onto two 
blood agar plates to determine any contamination of non-
mycobacterial organisms.
Screening samples for antimycobacterial activity 
(M. tuberculosis H37Rv) using automated 
radiometric respiratory technique
The radiometric respiratory technique using the BACTEC 460 
instrument was used for susceptibility testing against M. tu-
berculosis as described previously [25-27]. Solutions of all the 
compounds were prepared in DMSO to yield a final test con-
centration of 20.0 μg/mL in the BACTEC 12B vials containing 
4 mL of 7H12 medium broth. Every vial was supplemented 
with antimicrobial PANTA solution (Polymyxin B, Ampho-
tericin B, Nalidixic acid, Trimethoprim and Azlocillin; Becton 
Dickinson and Company, Ferndale, South Africa). Control ex-
periments showed that a final concentration of DMSO (1%) 
in the medium had no adverse effect on the growth of M. 
tuberculosis. Isoniazid (Sigma Chemical Co., South Africa), 
was used as the positive drug control. A homogenous culture 
(0.1 mL) of M. tuberculosis, yielding 1×104 to 1×105 CFU/mL, 
was inoculated in the vials containing the compounds as well 
as in the control vials. Three sample-free vials were used as 
controls (medium+1% DMSO): two vials (V1) were inoculated 
in the same way as the vials containing the samples, and one 
(V2) was inoculated with a 1:100 dilution of the inoculum 
(1:100 control) to produce an initial concentration represent-
ing 1% of the bacterial population (1×102 to 1×103 CFU/
mL). Mycobacterium growing in 7H12 medium containing 
14C- labelled substrate (palmitic acid) use the substrate and 
produced 14CO2. The amount of 
14CO2 detected (reflecting 
the rate and amount of growth occurring in the sealed vial) 
is expressed in terms of the growth index (GI) [28]. Inoculated 
bottles were incubated at 37 °C and each bottle was assayed 
at 24 h intervals at approximately the same hour (±2 h) until 
cumulative results were interpretable to measure the GI or 
until the GI of the V2 control reached a reading ≥30. The dif-
ference in the GI values of the last two days is designated as 
∆GI. The ∆GI readings of the vials containing the test samples 
were compared with the V2 control vial. If the ∆GI values of 
the vials containing the test compounds were less than that 
of V2, the population was reported to be susceptible to the 
compound. Each test was replicated three times. Whenever 
results suggested contamination (e.g., large, rapid increase in 
GI), the bottles were inspected, Ziehl-Neelsen (ZN) staining 
was carried out and a 100.0 μL of the suspected vial medium 
was streaked on blood agar plates to determine whether the 
visible microbial growth was organisms other than Mycobac-
terium tuberculosis.
Automated radiometric respiratory detection 
of resistant M. tuberculosis susceptibility AW4/2 
clinical strain
For preliminary studies, the derivatives were tested against 
a drug-sensitive strain of M. tuberculosis only at 20.0 µg/
mL conentration. Five derivatives completely inhibited the 
growth of the mycobacteria and these were further selected 
for testing at two concentrations, namely, 20.0 and 5.0 µg/
mL against a two drug-resistant strain of M. tuberculosis (AW 
4/2). The latter was obtained from a clinical specimen (MRC, 
Pretoria, South Africa) and prepared in the same manner as 
the H37Rv strain, mentioned before (see 2.2). The samples 
were dissolved in 100% DMSO to obtain stock concentra-
tions of 2.0 mg/mL to yield a final test concentration of 20.0 
μg/mL and 5.00 μg/mL in the BACTEC 12B vials. The as-
say was carried out as mentioned for the H37Rv screening, 
test samples were prepared in triplicate and the assay per-
formed on two separate occasions. The two drug-resistant 
test organism (resistant to both INH and ETH) was used as 
the drug-control for these bioassays at a final concentration 
of 0.2 µg/mL.
Cytotoxicity on differentiated U937 cells
The human promonocytic cell line U937 (ATCC available from 
Highveld Biological (Pty) (Ltd), (Sandringham, South Africa) 
was maintained in complete medium (RPMI 1640 medium 
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[pH 7.2], with 10% heat inactivated foetal calf serum (FCS), 
2 mM L-glutamine and a 0.1% antimicrobial solution con-
sisting of pennicilin, streptomycin and fungizone). Reagents 
were procured from Highveld Biological (Pty) (Ltd) (San-
dringham, South Africa). The U937 cell concentration was 
adjusted to 1×105 cells/mL, seeded into the inner wells of 
a 96-well tissue culture plate and treated with 0.10 μg/mL 
phorbol 12-myristate 13-acetate (PMA; Sigma) for 24 h at 37 
oC in an atmosphere of 5% CO2 to induce differentiation into 
macrophage-like cells [29, 30]. After the incubation period, 
the differentiated U937 cells were washed three times with 
phosphate-buffered saline (PBS), and adherent monolayers 
were replenished with complete medium without antibiotics. 
Cytotoxicity was measured by the 2,3-bis(2-methoxy-4-nitro-
5-sulfophenyl)-5-[(phenylamino)carbonyl]-2-H-tetrazolium 
hydroxide (XTT) method using the Cell Proliferation Kit II 
(Roche Diagnostics GmbH) as described by the method of 
Mahapatra et al. (2007) [31]. The pure compounds 6a and 
6b were made up to a stock concentration of 20.00 mg/mL 
and serially diluted to start with a concentration of 200.0 to 
1.562 µg/mL from the first wells to the last in the microti-
tre plates. The anti-tubercular drug, INH was diluted in the 
same way. These dilutions were added to the inner wells 
of the microtiter plate and incubated for 72 h. After 72 h, 
50.0 μL of XTT reagent (0.3 mg/mL) was added to the wells 
and the plates were then incubated for 1-2 h. The positive 
drug, (Actinomycin D; Sigma), at a final concentration range 
of 5.0×10-2 to 3.9×10-4 µg/mL, was included. DMSO (0.04%) 
was added to serve as the control for cell survival. The assay 
was carried out in triplicate. After incubation, the absorbance 
of the colour complex was spectrophotometrically quantified 
using an ELISA plate reader (PowerWave XS, Bio-Tek), which 
measured the OD at 450 nm with a reference wavelength of 
690 nm. GraphPad Prism 4.03 software was used to statisti-
cally analyse the fifty percent inhibitory concentration (IC50) 
values. The IC50 was defined as the concentration of the 
compounds at which absorbance, and thus cell viability, was 
reduced by 50%.
Parallel intracellular MIC determination and cell 
supernatant harvesting for immune modulation: 
U937 cell line.
The cells were infected with M. tuberculosis by diluting a 
concentration of actively growing bacilli into the cell culture 
medium and incubating with the cells over sixteen hours. 
The samples were then added to verify antimycobacterial ac-
tivity intracellularly and the resultant cell supernatants were 
analyzed to determine possible immunomodulation by these 
compounds.
Preparation of cells and mycobacteria
U937 cells were cultured, plated in 96-well plates at 1×105 
cells/mL and differentiated as described in section 2.5. My-
cobacterium tuberculosis H37Rv was maintained as previ-
ously described (section 2.2). Three week-old colonies were 
scraped from LJ slants and a concentration of 6×105 CFU/mL 
was prepared in 10% heat inactivated FCS RPMI medium 
supplemented with a final concentration of 2.5% PANTA pre-
vent contamination by non-mycobacterial organisms.
In vitro Mycobacterium tuberculosis infection of 
U937 cells. 
Differentiated U937 cells were washed three times with phos-
phate-buffered saline (PBS), and adherent monolayers were 
replenished with complete medium without antibiotics. U937 
cells (1×105 cells/mL) were infected with mycobacteria (3×105 
CFU/mL) using bacteria-to-cell ratios of 3:1. The macrophages 
were allowed to phagocytose the bacteria for 16 h at 37 
°C in a humidified atmosphere of 5% CO2. In preliminary 
experiments phagocytosis of M. tuberculosis was evaluated 
by light microscopy using ZN staining. To evaluate the effect 
of M. tuberculosis phagocytosis on cell mortality, cells were 
periodically counted using the trypan blue dye (0.4%, Sigma) 
exclusion method. M. tuberculosis causes lysis and cell death 
in 10-14 days. In preliminary experiments, it was observed 
that a 10:1 ratio between M. tuberculosis and cells has a 
high cytopathic effect, a 5:1 ratio is better in terms of cell 
viability (25% in cultures with M. tuberculosis versus 45% in 
control cultures), while the 3:1 ratio gave the best cell viability 
(38% in cultures with M. tuberculosis versus 45% in control 
cultures). Therefore 3 bacilli/cell was the M. tuberculosis/cell 
concentration used in all the experiments.
Intracellular MIC assay and parallel collection of 
cell supernatants for immune modulation: U937 
cell line
Preparation of sample solutions
Samples tested for determining the intracellular antimyco-
bacterial and immunomodulatory activity included sample 
6a and 6b at their IC50, and half MIC concentrations as their 
MIC concentrations would lead to loss of cell viability. The 
anti-tubercular drug INH was included at half MIC, MIC and 
IC50 concentrations of 0.10, 0.20 and 200 μg/mL. The high-
est concentration of DMSO present in the assay (0.25%) was 
included as the vector control to measure cell viability. To 
ensure for enough volume of sample (two sets of samples, for 
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infected and uninfected macrophages, each sample tested 
in triplicate and samples replaced at 24 and 72 h after the 
first sample addition) a volume of 4 mL for each sample con-
centration was prepared in RPMI medium (no supplementa-
tion) with a DMSO concentration of no higher than 0.25%. 
Sample solutions were prepared fresh on the first day of the 
experiment (designated as 0 h) and the remaining sample 
solutions were stored at 4 °C until used again at 24 and 72 h 
after initial sample addition. Cell viability was not affected as 
the highest concentrations of samples tested never exceeded 
the IC50 concentrations of the individual samples.
Confirming the infective dose
After the infection period the cells were washed with PBS 
an additional three times to remove any unphagocytosed, 
extracellular bacilli. To confirm the infection dose for all the 
samples, designated wells containing untreated, infected 
macrophages were lysed with 0.25% (w/v) sodium dodecyl 
sulfate (SDS, Sigma), performing 10-fold serial dilutions (100, 
10-1, 10-2, 10-3 and 10-4) and plating the lysate on Middle-
brook 7H11 agar (Fluka Analytical, Sigma) for viable count 
determinations of intracellular organisms.
Intracellular MIC assay and supernatant collection
After the 16 h phagocytosis, 200.0 µL of fresh medium con-
taining the desired test samples was transferred to each mac-
rophage containing well (replicates of three per treatment). 
The cell supernatants were collected at 24, 72 and 120 h, 
transferred to sterile Eppendorf tubes and frozen at -70 °C for 
subsequent cytokine analysis. The sample-medium mixtures 
were replaced at 24 and 72 h. The culture was enumerated 
after lysing the macrophages with 0.25% SDS on day 5 (120 
h). The lysed contents of each well were resuspended by 
multiple passages through a 25-gauge needle, and 100.0 
µL was transfered to 7H11 agar medium for viable count de-
terminations, serial 10-fold dilutions of the lysate (100, 10-1, 
10-2, 10-3 and 10-4) was included. An additional set of un-
infected macrophages were handled and treated in identical 
conditions to the infected set of macrophages, to investigate 
the immunomodulatory effects of the samples on the mac-
rophages alone. Methods used for intracellular infection were 
adapted from Passmore et al. (2001) [29], Rastogi et al. (1996) 
[32] and Lall et al. (2005) [33].
CFU enumeration
The conventional method for viable count determinations of 
intracellular M. tuberculosis involved plating of 10-fold serial 
dilutions (100, 10-1, 10-2, 10-3 and 10-4) of sample lysate 
directly on 7H11 agar plates in triplicate for each concen-
tration of samples and controls [32, 34]. The plates were 
incubated at 37 °C in 5% CO2 atmosphere for 3-4 weeks 
followed by CFU enumeration via the colony counting system 
ColorQCount® (Spiral Biotech, Model 530). Appropriate posi-
tive and negative controls were included. A compound was 
considered bactericidal if it effectively reduced the bacteria 
viable counts in the test sample compared with the initial 
inoculum added at the time of compound addition [32, 34].
Cytokine detection via Cytometric Bead Array 
(CBA) analysis
Cell culture supernatants were thawed once and examined 
for IL-2, IL-4, IL-5, IL-10, IFN-γ and TNF-α concentrations by 
multiplex cytokine array analysis performed by using the Cy-
tometric Bead Array (CBA) method using the Human Th1/Th2 
Kit (BD-Biosciences). Using the same lots of samples, IL-12 
levels were acquired with a commercial Human IL-12p70 Flex 
Set (BD-Biosciences). The IL-12 assay was run separately but in 
parallel with the Th1/Th2 Kit. The methods used were based 
on literature procedures [12-35, 36]. Assay procedures were 
performed as specified by the manufacturer. The methods for 
both the Th1/Th2 Kit and the Flex Set are similar, except that 
with the Th1/Th2 Kit, six cytokines were measured simulta-
neously, six standard curves (each ranging from 0 to 5000 
pg/mL) and six cytokine results were acquired from one set 
of mixed calibrators and one test sample (cell supernatant) 
whereas with the Flex Set only the one cytokine (IL-12) was 
measured from a single test sample, and only one standard 
curve (0 to 2500 pg/mL) from the one calibrator was ob-
tained. Briefly, the appropriate Capture Beads were mixed 
on a Vortex mixer before adding 50.0 μL to each of the as-
say tubes. Fifty microlitres of the relevant phycoerythrin (PE) 
detection reagent was then added to the assay tubes. For 
each of the test samples, 50.0 μL of cell supernatant was 
added to the test assay tubes and 50.0 μL of the cytokine 
standard dilutions were added to the control assay tubes. The 
assay tubes were then incubated for 3 h at room temperature 
away from direct exposure to light. During the incubation, 
the Cytometer Setup procedure was performed. After the 
incubation time, 1.00 mL of wash buffer was added to each 
assay tube and centrifuged at 200×g for 5 minutes. The su-
pernatant from each assay tube was carefully aspirated (not 
to disturb the bead pellet) and discarded. To resuspend the 
bead pellet, 300 μL of wash buffer was added to each assay 
tube and mixed on a Vortex for 3-5 seconds before plating 
the samples out in 96-well microtiter plates. Acquisition was 
performed with flow cytometry utilising the BD FACSArray 
bioanalyzer and the data was analyzed with the FCAP Array 
software. The sensitivity for each cytokine using the BD CBA 
Human Th1/Th2 Cytokine Kit is as follows: IL-2, 2.6 pg/mL; 
IL-4, 2.6 pg/mL; IL-5, 2.4 pg/mL; IL-10, 2.8 pg/mL; TNF-α, 2.8 
pg/mL; IFN-γ, 7.1 pg/mL and for the Human IL-12p70 Flex Set 
the limit of detection is 0.6 pg/mL These theoretical limits of 
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detection is defined as the corresponding concentration at 
two standard deviations above the median fluorescence of 
20 replicates of the negative control (0 pg/ml).
Results and Discussion
Antimycobacterial activity 
Antimycobacterial activity was assayed using the BACTEC ra-
diometric assay, which is a well-documented technique for 
testing susceptibility of M. Tuberculosis [37-39]. Preliminary 
studies were performed on a drug-susceptible strain of M. 
tuberculosis H37Rv (sensitive to the first-line antituberculosis 
drugs; INH, RIF, ETH and STR). The antituberculosis positive 
drug, isoniazid (INH), was used as a control and it inhib-
ited the growth of M. tuberculosis at 0.2 µg/mL during the 
screening assay. A compound is considered to be active if the 
difference in GI (∆GI) of the test compounds is less than that 
of the control vial. If the ∆GI values of the vials containing the 
test samples were less than the control vials, the population 
was reported to be susceptible to the compound and if it 
was equal to or greater than that in the control vials, the test 
organisms were considered to be resistant to the drugs. The 
vast majority of quinoline derivatives tested, namely, 4-ami-
no-2-arylquinolines, 4-amino-2-aryl-3-bromo/iodoquinolines 
and 4-amino-2, 3-diarylquinolines contain a primary 4-amino 
group (Figure1). The 2-aryl-3-iodo-4-methoxyquinolines and 
2, 3-diaryl-4-methoxyquinolines were included for structure 
activity relationship analysis. Although the naturally occurring 
4-methoxy-2-phenylquinoline and its 2-(methylenedioxyphe-
nyl) analogue have recently been found to show inhibitory 
activity against Mycobacterium tuberculosis H37Rv [11] results 
from preliminary assays (Table 1) using drug susceptible strain 
of M. tuberculosis showed no activity for all the 4-methoxy-
2-aryl-3-iodoquinolines 7a–d (MPOMe16–MPOMe19) and 
2,3-diaryl-4-methoxyquinoline derivatives 8a–d (MPOMe20–
MPOMe23). Most of the 4-amino-2-aryl-3-halogenoquino-
lines 3–5 (MPHJA01, MPHJA03–MPHJA10) displayed reduced 
or lack of activity against the drug-sensitive strain (results 
of inactive compounds not shown) with the exceptions of 
3b (MPHJA02) and 4-amino-3-iodo-2-(4-methoxypheyl)quin-






3a (MPHJA01) H H
3b (MPHJA02) H Cl
3c (MPHJA03) H OMe
4a (MPHJA04) Br H
4b (MPHJA05) Br F
4c (MPHJA06) Br Cl
4d (MPHJA07) Br OMe
5a (MPHJA08) I H
5b (MPHJA09) I F
5c (MPHJA10) I Cl
5d (MPHJA11) I OMe
6a (MPHJA12) -C6H5 H
6b (MPHJA13) -C6H5 F
6c (MPHJA14) -C6H5 Cl






7a (MPOMe16) I H
7b (MPOMe17) I F
7c (MPOMe 8) I Cl
7d (MPOMe19) I OMe
8a (MPOMe20) -C6H5 H
8b (MPOMe21) -C6H5 F
8c (MPOMe22) -C6H5 Cl
8d (MPOMe23) -C6H5 OMe
Figure 1.  List of the 4-heteroatom 
substituted 2-arylquniline 
derivatives evaluated for 
antimicobacterial activity.
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oline 5d (MPHJA11). Only the five compounds 3b, 5d, 6a, 
6b and 6d bearing primary 4-amino group exhibited signifi-
cant inhibition of drug sensitive M. tuberculosis. The strong 
conjugative effect of the 4-amino group due to compatible 
C2P-N2P pi bond interaction has been found to render the 
quinoline ring sufficiently basic so that it is protonated at 
physiological pH (pK>8.4) [40, 41]. The moderate conjugative 
effect of oxygen atom of the 4-methoxy group, on the other 
hand, would lead to reduced basicity of the quinoline ring 
and therefore less or no activity for the 4-methoxyquinoline 
derivatives. Despite the presence of a primary 4-amino group, 
which is expected to increase electron density at N1 and C3 
atoms to led to increased basicity of the quinoline ring, all 
the 3-halogeno derivatives with the exception of 4-amino-
3-iodo-2-(4-methoxyphenyl)quinoline 5d showed no activity 
against the drug sensitive strain. Increased activity displayed 
by 5d and the 4-amino-2, 3-diarylquinoline derivatives 6a, b 
and d against drug sensitive strain, may point to electronic 
effect of the 3-substituent on the electron density of the 
heterocyclic ring and also the basicity of N1. In our view, the 
electron withdrawing inductive effect of bromine or iodine 
reduces the electron density at C-3 leading to reduced elec-
tron density of the heterocyclic ring and therefore the basic-
ity of N1. The increased propensity of the 4-methoxy group 
for electron donation to the phenyl ring of 5d, on the other 
hand, would lead to increased electron density on C-2 and 
in turn counteract the relatively weak electron withdrawing 
inductive effect of the 3-iodo group (Figure 1).
Based on these preliminary results, the five 4-aminoqui-
nolone derivatives 3b, 5d, 6a, 6b and 6d were evaluated 
against drug resistant strain, M. tuberculosis H37Rv, and for 
minimum inhibitory concentrations (MIC) determination (Ta-
ble 1). Increased activity against drug-resistant strains was 
observed for the 4-amino-2-(4-chlorophenyl)quinoline 3b 
(MPHJA02) and the 4-amino-2,3-diarylquinoline derivatives 
6a (MPHJA12), 6b (MPHJA13) and 6d (MPHJA15). Compound 
5d however showed no activity against the drug-resistant 
strain at any of the concentrations employed. Although 
4-amino-2,3-diphenylquinoline 6a was not the most active 
compound during the preliminary screening against the drug 
sensitive strain, it showed increased activity against of M. 
tuberculosis H37Rv at 20.0 μg/mL than the other analogues 
(Table 1). Reduced activity displayed by 3b against the drug 
resistant strain points to the importance of the 3-phenyl sub-
stituent on activity (Table 1).
The observed trend in activity for the 4-amino-2, 3-dia-
rylquinolines, on the other hand, is presumably the result of 
a combination of electronic and steric effects of the 2-aryl 
group. Accordingly, activity seems to decrease (-C6H5>4-
FC6H4->4-MeOC6H4-) with increasing size of the substituent 
(H<F<OCH3) at the para position of the 2-phenyl ring.
Intracellular antimycobacterial activity
The enumerated CFU/mL of mycobacteria treated with test 
samples at 120 h were compared with the initial inoculum 










5.00 (μg/mL) 20.0 (μg/mL)
3b (MPHJA02) 1.00 59.5 ± 4.95 5.00 ± 4.24 > 5.00 < 20.0 8.445± 0.048
5d (MPHJA11) 0.00 86.0 ± 14.1 41.0 ± 7.07 > 20.0 6.752±0.034
6a (MPHJA12) 8.00 76.00 ± ns 1.00 ± 0.00 > 5.00 < 20.0 18.43±0.421
6b (MPHJA13) 8.00 85.0 ± 18.4 3.00 ± 1.41 > 5.00 < 20.0 14.37±0.323
6d (MPHJA15) 0.00 87.5 ± 10.6 12.5 ± 3.54 > 5.00 < 20.0 7.968±0.178
V2e 23.0 36.0 ± 1.41 - -
INHf -3.00 40.1 ± 3.75 ≥ 0.20 > 200.0
Actinomycin D - - - 0.0038±0.0005
a  Growth index for samples active against the drug sensitive strain (H37Rv) at 20.0 μg/mL.
b Difference in growth index for the drug resistant strain (AW 4/2) as the mean ± standard deviation.
c  Minimum inhibitory concentration against drug resistant strain.
d  Fifty percent inhibitory concentration of differentiated U937 macrophage cell-growth as the mean ± standard deviation.
e  1:100 dilution of the inoculums (control vial), representing 1% of the mycobacterial population (1×102-1×103 CFU/mL).
f INH tested at the known MIC of 0.20 µg/ml.
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added at the time of compound addition (0 h), and a sample 
was considered bactericidal if it effectively reduced the bac-
teria viable counts (a one log decrease or 90% inhibition). 
The number of enumerated CFU’s for the growth control 
(2.20×105 CFU/mL) corresponded well with the amount of 
bacilli used to infect the cells (3.00×105 CFU/mL). As expect-
ed, the positive drug INH inhibited the mycobacteria by a 
one log reduction in viable bacterial counts, from 105 to 104 
CFU/mL at both concentrations tested (Table 2/Figure 2). 
The 4-amino-2, 3-diarylquinolines 6a and 6b, on the other 
hand, did not exhibit any significant inhibition of intracellular 
M. tuberculosis growth at the concentrations tested (Table 
2/Figure 2). The direct MIC values of 6a and 6b are closer to 
20.00 μg/mL and had to be tested intracellulary at sub-MIC 
concentrations, below or equal to their IC50 concentrations 
(Table 2) to avoid loss of U937 cell viability. Still, the general 
inactivity of 6a and 6b at their IC50 concentrations is surpris-
ing as the IC50 concentrations are not far from the proposed 
MIC values (Table 2) and these compounds are fairly fat 
soluble and would readily cross the cell membrane. Another 
reason for sample inactivity could be physicochemical, espe-
cially considering a pH change inside of the macrophages 
where the lysosomes containing the M. tuberculosis has a 
much lower pH as the rest of the cell, which could have a 
drastic effect on the structure and activity of the compounds. 
This acidic environment affects the action of anti-TB drugs 
such as streptomycin (activity reduced) and pyrazinamide (ac-
tivity increased) (7) (Table 2 and Figure 2).
Immunomodulation
In response to infection with mycobacteria, macrophages pro-
duce specific cytokines including the Th1-type cytokine, IL-12. 
These cytokines synergistically stimulate production of IFN-γ 
Table 2.  Intracellular growth inhibition of Mycobacterium tu-
berculosis 120 h post-treatment.
Treatment Viable count (CFU/mL)a
H37Rvb (7.00 ± 1.62) × 105
INH
0.10 µg/mLc (5.80 ± 2.10) × 104
0.20 µg/mLd (1.20 ± 0.18) × 104
6a
10.0 µg/mLc (6.30 ± 0.42) × 105
18.0 µg/mLe (2.50 ± 0.68) × 105
6b
10.0 µg/mLc (3.60 ± 0.44) × 105
14.0 µg/mLe (2.70 ± 0.12) × 105
a  Viable counts were performed by plating serially diluted cultures 
from cell lysate onto 7H11 agar medium. Expressed as the mean 
± standard deviation.
b  H37Rv inoculum containing 0.25% DMSO (initial infective dose 
determined as (2.20 ± 0.41) × 105 CFU/mL).
c  At ½ MIC concentration.
d  At MIC concentration.
e  At IC50 concentration.
Figure 2.  Intracellular growth inhibition 
of Mycobacterium tuberculosis 
after 120 h of sample 
treatment.
All sample treatment results statistically 
significant comparisons for CFU/mL: 
P>0.05 when compared to the 120 h 
H37Rv inoculum containing 0.25% DMSO. 
Viable counts were performed by plating 
serially diluted cultures from cell lysate 
onto 7H11 agar medium. Viable counts 
have been expressed as percentage 
growth.
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Table 3.1. Cytokine profiles (pg/mL) of sample treated, uninfected macrophages (72 h treatment).
Test Sample
Th1 Cytokines Th2 Cytokines
IL-2 IL-12 IFN-γ TNF IL-4 IL-5 IL-10
Control 0.00 0.00 0.00 0.00 0.00 1.31 0.00
DMSO (0.25%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
INH:
½ MIC (0.01 µg/mL) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MIC (0.02 µg/mL) 0.00 1.12 0.00 0.00 1.85 0.00 1.39
IC50 (200.0 µg/mL) 0.00 0.00 0.00 0.00 0.00 0.00 2.17
6a
½ MIC (10.0 µg/mL) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
IC50 (18.0 µg/mL) 0.00 1.23 0.00 0.00 0.00 1.22 2.17
6b
½ MIC (10.0 µg/mL) 0.00 1.70 0.00 0.00 0.00 0.00 0.00
IC50 (14.0 µg/mL) 0.00 1.41 0.00 0.00 0.00 0.00 1.68
Table 3.2. Cytokine profiles of M. tuberculosis infected sample treated macrophages (72 h treatment).
Test Sample
Th1 Cytokines Th2 Cytokines
IL-2 IL-12 IFN-γ TNF IL-4 IL-5 IL-10
Control 0.00 0.00 0.00 0.00 0.00 0.00 1.88
DMSO (0.25%) 0.00 1.30 0.00 0.00 0.00 0.00 0.00
INH:
½ MIC (0.01 µg/mL) 0.00 1.14 0.00 0.00 1.11 0.00 2.03
MIC (0.02 µg/mL) 0.00 0.00 0.00 0.00 1.85 1.11 2.03
IC50 (200.0 µg/mL) 0.00 0.00 0.00 0.00 0.00 0.00 1.39
6a
½ MIC (10.0 µg/mL) 0.00 1.47 3.49 1.76 3.69 1.70 2.55
IC50 (18.0 µg/mL) 6.30 1.23 22.31 8.21 17.19 3.91 8.81
6b
½ MIC (10.0 µg/mL) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
IC50 (14.0 µg/mL) 0.00 1.51 0.00 0.00 2.92 0.00 1.78
 
by CD4+ T cells and NK cells (lymphocytes). IFN-γ ligand is 
known to bind to its receptor on the macrophage cell surface 
and to activate the macrophage resulting in enhanced TNF-α 
production, production of other cytokines and chemokines, 
upregulation of MHC class II expression, enhanced antigen 
processing, and production of reactive oxygen species [42]. 
An infection is likely to induce a complex cytokine profile, 
including both stimulatory and inhibitory cytokines. Since 
multiple cytokine effects on macrophages are exerted simul-
taneously, the net result may be ultimately determined by the 
nature of cytokines present, the timing of their production 
and their relative concentration levels. In this investigation, 
the level of seven cytokines (Interleukin [IL] -2,-4,-5,-10,-12, 
Interferon gamma [IFN-γ] and Tumour necrosis factor alpha 
[TNF-α]) were measured via Cytometric Bead Array (CBA), a 
particle based immunoassay combined with flow cytometry. 
The levels of cytokine production was very low (Table 3.1 
and 3.2) mainly due to the experimental circumstances where 
the supernatant was initially collected and stored at 24 h after 
incubation and replaced with fresh sample-containing me-
dium and only collected and stored again after another 48 h. 
Due to technical difficulties, only the supernatants collected 
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72 h after infection are reported herein. Cytotoxicity was 
measured 72 h after sample addition and can thus be cor-
related with the cytokine results. Considering the experimen-
tal outcomes for the naive (uninfected) macrophages (Table 
3.1), none of the test samples produced any toxic effects as 
most samples exhibited minor cytokine production similar to 
that of the untreated differentiated cells and the DMSO (0.25 
%) control (Table 3.1. and Table 3.2). 
At first glance it seems as though the data generated from 
the cytokines profiles in the context of this study has limited 
value. However, relative to the naive cells, the degree of cyto-
kine production in the infected cells treated with samples 6a 
and 6b was greater with respect to the range and concentra-
tion of cytokines (Table 3.1). Cells with concomitant produc-
tion of different cytokines harbour multiple effect or func-
tions and are functionally superior to their single-cytokine 
counterparts [43]. Therefore the functionality of the infected 
cells is increased when treated with 6a and 6b especially 
upon treatment with 6a. This effect is not attributed to intra-
cellular antimycobacterial activity of 6a as no significant inhi-
bition was observed (Table 2/Figure 2). Infected cells treated 
with compound 6a represent the only sample that induced 
production of all seven cytokines measured during this study 
and at significantly higher levels than any of the other test 
samples. This is interesting since CD4+ lymphocytes rather 
than macrophages are the primary cells for IFN-γ and IL-2 
production during M. tuberculosis infection and therefore 
low levels of these two Th1 cytokines were expected. System 
6a induced production of both these Th1 cytokines whereas 
the other samples or controls did not induce the produc-
tion of IFN-y or IL-2. Untreated cells (control cells) infected 
with M. tuberculosis did not express any cytokines save for 
the Th2 cytokine IL-5 at a negligible mean concentration of 
1.31 pg/mL. Similar results were observed for TNF where only 
infected cells treated with 6a produced this important cyto-
kine. TNF plays a critical role in the control of mycobacteria, 
which drives granuloma development and also concentrates 
antimycobacterial drugs within macrophages [44]. However, 
TNF-α does not play a strictly beneficial role in tuberculosis 
pathogenesis and has been referred to as a “double-edged-
sword”. Increased plasma TNF-α levels have been associated 
with clinical deterioration early in the treatment of severe 
tuberculosis. TNF may have deleterious roles such as overt 
tissue damage in the setting of overproduction, as TNF-α is 
the cytokine widely thought to be responsible for the effects 
of tuberculosis including fever, weight loss, tissue necrosis 
and the Koch phenomenon [45]. Treatment with samples 6a 
and 6b slightly altered the production of both type 1 and 
2 cytokines during infection, but did not induce a marked 
polarized type 1 to type 2 state but rather a mixed Th1/
Th2 response. Very low levels of Th2 cytokines (especially 
IL-4 and IL-10) are needed to negate the effects of Th1 cy-
tokines even if the latter are at higher concentrations [46]. 
In addition, the Th1-type cytokine IFN-γ is synthesized earlier 
than the type 2 cytokine, IL-4 [17]. According to a previ-
ous report, when carried out gene expression analyses using 
the reverse transcription polymerase chain reaction for the 
iNOS and the cytokines IL-1, IL-12, IL-18, TNF-α, IFN-α, and 
IFN-γ in non-infected and in Leishmania major-infected RAW 
264.7 cells was carried out, low mRNA levels in non-infected 
cells, but considerably up-regulated transcript expressions in 
infected cells. Production of IFN-γ mRNA was also stimulated 
for the methanol-insoluble fraction (MIF) and gallic acid. The 
methanol-soluble fraction and umckalin did not show any 
significant gene-inducing capabilities. 
Conclusion
The presence of a primary amino group at C-4 and phenyl 
ring at C-3 and the accompanying increased basicity of the 
quinoline ring as well as electronic effect and lipophilicity 
of the substituent on the para position of the 2-phenyl ring 
seem to be critical for the activity of the 2, 3-diarylquinoline 
derivatives. Overall, the production of cytokines from this 
specific experiment gives an idea of the amount of individual 
cytokines produced daily instead of a cumulative response 
to the test samples during infection. Compound 6a holds 
potential to modulate the functionality of M. tuberculosis 
infected macrophages. Research is currently underway in our 
laboratories to prepare series of analogues substituted with 
various aryl or heteroaryl rings at the 3-position for further 
in vitro immunoassays with macrophages from PBMC’s and 
co-cultures with lymphocyte cells. 
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